Treatment Patterns and Health Outcomes Among Patients with Radioiodine-Refractory Differentiated Thyroid Cancer in the United States and Western Europe
Gianoukakis, A.G, Flores, N.M, Pelletier, C.L, DiBonaventura, M, Forsythe, A, Wolfe, G, Rege, J, Taylor, M.H
Published in Value in health (01.11.2014)
Published in Value in health (01.11.2014)
Get full text
Journal Article
82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies
Gianoukakis, A.G., Arnold, S.M., Kahn, S.A., Taylor, M., Garralda, E., Krebs, M.G., Arkenau, H-T., Clark, L., Fisher, G., Subbiah, V.
Published in Journal of thoracic oncology (01.04.2023)
Published in Journal of thoracic oncology (01.04.2023)
Get full text
Journal Article
1295P EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI
Garralda, E., Clark, L., Wang, J.S., Gianoukakis, A.G., Taylor, M.H., Morgensztern, D., Arnold, S.M., Spigel, D.R., Liu, S.V., Krebs, M.G., Forster, M.D., Garcia-Corbacho, J., Paz-Ares, L.G., Fisher, G., Brook, S., Patel, S., Arkenau, H-T., Overstreet, B., Yalamanchili, G., Garrido Lopez, P.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
Brose, M.S., Panaseykin, Y., Konda, B., Fouchardiere, C. de la, Hughes, B.G.M., Gianoukakis, A.G., Park, Y.J., Romanov, I., Krzyzanowska, M.K., Binder, T., Dutcus, C., Xie, R., Taylor, M.H.
Published in Annals of oncology (01.11.2020)
Published in Annals of oncology (01.11.2020)
Get full text
Journal Article
1917P Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial
Haugen, B., French, J.D., Worden, F., Konda, B., Sherman, E.J., Dadu, R., Gianoukakis, A.G., Mccue, S., Foster, N., Bowles, D.W., Wirth, L.J.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
1746P Health-related quality-of-life (HRQoL) analyses from study 211: A phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN)
Taylor, M.H., Leboulleux, S., Panaseykin, Y., Konda, B., Fouchardiere, C. de la, Hughes, B.G.M., Gianoukakis, A.G., Park, Y.J., Romanov, I., Krzyzanowska, M.K., Garbinsky, D., Sherif, B., Pan, J.J., Binder, T.A., Sauter, N., Xie, R., Brose, M.S.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
PCN1 - Treatment Patterns and Health Outcomes Among Patients with Radioiodine-Refractory Differentiated Thyroid Cancer in the United States and Western Europe
Gianoukakis, A.G., Flores, N.M., Pelletier, C.L., DiBonaventura, M., Forsythe, A., Wolfe, G., Rege, J., Taylor, M.H.
Published in Value in health (01.11.2014)
Published in Value in health (01.11.2014)
Get full text
Journal Article